A significant association was found between the SHMT2 genetic variation, its expression, and increased susceptibility to NAFLD and MetS in human populations, as well as SHMT2’s stage-specific regulation of the onset and progression of NAFLD in the model animals. This evidence concerns the gene SHMT2 and metabolic dysfunction-associated steatotic liver disease.